Please assess the completion status of the following clinical trial:

Trial Title: Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female between 16- to 26-years-old~* Has never had Pap testing or has only had normal Pap (Papanicolaou) test results~* For the immune memory substudy in the extension (Cohort 1): was randomized to V503 in the base study and was in the per-protocol immunogenicity population for ≥1 HPV type~* For the 3-dose V503 vaccination substudy in the extension (Cohort 2): was randomized to GARDASIL in the base study and received ≥1 dose of GARDASIL~Exclusion Criteria:~* History of an abnormal cervical biopsy result~* History of a positive test for HPV~* History of external genital/vaginal warts~* Currently a user of any illegal drugs or an alcohol abuser~* History of severe allergic reaction that required medical attention~* Are pregnant~* Received marketed HPV vaccine or participated in an HPV trial~* Currently enrolled in a clinical trial~* Currently has or has a history of certain medical conditions or is currently taking or has taken certain medications (details will be discussed at the time of consent.)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Low-dose V503 (Type: EXPERIMENTAL): V503 (9-Valent Human Papillomavirus \[HPV\] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
- Mid-dose V503 (Type: EXPERIMENTAL): V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
- High-dose V503 (Type: EXPERIMENTAL): V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
- Gardasil (Type: ACTIVE_COMPARATOR): Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).